Biotechnology

Auburn University is launching advanced biomedical engineering programs to fuel Alabama's booming biotech sector, a strategic investment in human capital.

Vertex's new CF drug, ALYFTREK, clears a major hurdle in Canada, promising a once-daily treatment and new hope for patients previously left behind.

Shilpa Medicare and Orion Corp. partner on a nivolumab biosimilar, challenging Big Pharma and promising affordable access to a vital cancer immunotherapy.

With a new ADC expert as CMO, Corbus Pharmaceuticals is advancing its dual pipeline. This move signals a critical phase for its cancer drug and obesity therapy.

With a breakthrough oral drug for a rare form of blindness, Belite Bio heads to a key symposium. Can it convince investors it can win a crowded race?

Invivyd's COVID-19 drug PEMGARDA loses its emergency status, sparking a high-stakes race for full approval and raising fears of a looming gap in patient care.

VERAXA Biotech is betting its future on its proprietary BiTAC technology, a strategic pivot that sharpens its focus amid a volatile market for cancer therapies.

A South Korean biotech's diabetes drug finds new purpose in fighting FSHD, backed by a foundation's innovative funding model that could reshape rare disease R&D.

Australian biotech Immuron hires a top dealmaker to land a partner for its novel C. diff therapy. The goal: secure funding and unlock a potential $400M market.

UK biotech Ananda Pharma advances its MRX1 drug to Phase 2 trials, targeting a debilitating chemotherapy side effect with no current effective treatment.

Novartis's acquisition of Myricx Bio isn't just a deal. It's a story of academic grit, venture capital vision, and a new blueprint for patient-centric cancer therapy.

A new partnership aims to use tiny, fully human antibodies to shuttle drugs past the blood-brain barrier, a move that could unlock a new era of treatments.

Immunomic Therapeutics begins human trials for ITI-9001, an saRNA vaccine aiming to rewrite the immune response to Japanese cedar pollen allergy.

An inside look at how Chengdu is pairing high-tech industrial might with aggressive global outreach to redefine itself as a critical node in tech and biotech.

NKGen Biotech signals a strategic pivot to Asia, leveraging its novel NK cell therapy, troculeucel, to tap into China's new, accelerated biotech pathways.

Revolution Medicines' zoldonrasib delivers high response rates in trials for RAS G12D pancreatic cancer, offering a beacon of hope against a lethal disease.

YD Bio is expanding its U.S. lab network, but the real story is its strategy: turning diagnostic tests into a vast data engine to power the future of cancer research.

At Boston's Wedbush Renal Summit, Hansa Biopharma showcases its game-changing transplant drug, signaling a major strategic play for the lucrative U.S. market.

A massive financing round for deupirfenidone isn't just about a potential new IPF drug; it's a masterclass in biotech strategy, validating a model that promises value for all.

Molecular Partners and Orano Med begin human trials for a novel radiopharmaceutical, hoping to unlock a new front against small cell lung cancer.